Vericel Announces Preliminary Third Quarter 2020 Total Net Revenues of $32 Million
October 14, 2020 08:00 ET
|
Vericel Corporation
Double-Digit Revenue, Implant and Biopsy Growth for MACI in the Quarter and Record Monthly Biopsies in September Approximately $4.6 Million of Operating Cash Flow for the Quarter ...
Vericel To Host Virtual Analyst and Investor Day on October 16, 2020
October 09, 2020 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Oct. 09, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, will host a virtual...
Vericel Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
September 16, 2020 07:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the recently...
Vericel to Present at Multiple Upcoming Investor Conferences
September 09, 2020 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced...
Vericel to Present at the 18th Annual Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2020
September 04, 2020 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick...
MediWound and Vericel Announce Acceptance of the First Delivery of NexoBrid to BARDA for Emergency Response Preparedness
August 25, 2020 07:00 ET
|
Vericel Corporation
YAVNE, Israel and CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that the...
Vericel Reports Second Quarter 2020 Financial Results
August 05, 2020 08:00 ET
|
Vericel Corporation
Product Revenues of $20.0 Million Reported for the Second Quarter Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation...
Vericel to Report Second-Quarter 2020 Financial Results on August 5, 2020
July 22, 2020 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the...
Vericel Announces Preliminary Second Quarter 2020 Financial Results and Provides Business Updates
July 09, 2020 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., July 09, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced...
Vericel Announces Submission of Biologics License Application to the FDA for NexoBrid for the Treatment of Severe Thermal Burns
June 30, 2020 07:00 ET
|
Vericel Corporation
CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug...